GlassScriptPhysician profile
Joseph P Greco
NPI 1881662567
$10,234.43
in general payments reported to CMS, 2019-2025
42 companies · $2,719 in 2025
The $2,719 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $661 · 2021: $1,086 · 2022: $1,297 · 2023: $1,720 · 2024: $2,147 · 2025: $2,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,578 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,578.45 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,480.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,177.68 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $873.11 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $784.82 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $778.90 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $723.02 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $633.84 | 2019-2025 | |
| Lilly USA, LLC | $567.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $361.95 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $331.61 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.90 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $246.05 | 2022-2025 | |
| Daiichi Sankyo INC. | $222.42 | 2020-2022 | |
| Abbott Laboratories | $206.80 | 2022-2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $166.12 | 2020-2025 | Zoryve |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Greco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.